The use of adipokines and myokines measured in serum or cerebrospinal fluid as biomarkers or disease modifiers in neurological disorders is limited. Their permeability to the blood–brain barrier is either unknown or overlooked. A novel classification of adipokines and myokines on the basis of their cerebrospinal fluid to serum ratio is warranted.
- Andreas Schäffler
- Andreas Schmid
- Thomas Karrasch